Amylyx Pharmaceuticals, Inc. (AMLX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Joshua B. Cohen
|
Co-Founder, Co-CEO & Director | 1.25M | -- | 1992 |
|
Mr. Justin B. Klee
|
Co-CEO & Director | 1.25M | -- | 1991 |
|
Mr. James M. Frates M.B.A.
|
Chief Financial Officer | 817.18k | -- | 1967 |
|
Dr. Camille L. Bedrosian M.D.
|
Chief Medical Officer | 1.01M | -- | 1953 |
|
Mr. Tom Holmes
|
Chief Technical Operations Officer | -- | -- | -- |
|
Ms. Lindsey Allen
|
Head of Investor Relations & Communications | -- | -- | -- |
|
Ms. Gina M. Mazzariello J.D.
|
Chief Legal Officer & General Counsel | 715.49k | -- | 1972 |
|
Ms. Linda A. Arsenault
|
Chief Human Resources Officer | -- | -- | -- |
|
Ms. Tammy Sarnelli
|
Global Head of Regulatory Affairs | -- | -- | -- |
|
Dr. Machelle Manuel Ph.D.
|
VP & Head of Global Medical Affairs | -- | -- | -- |
Amylyx Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 136
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
November 5, 2026 at 12:30 PM UTC
Amylyx Pharmaceuticals, Inc. Earnings Date
